Aristides Capital LLC Syndax Pharmaceuticals Inc Call Options Transaction History
Aristides Capital LLC
- $260 Million
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SNDX
# of Institutions
232Shares Held
96.9MCall Options Held
1.39MPut Options Held
543K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$140 Million7.14% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$130 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.95MShares$97.5 Million0.01% of portfolio
-
Morgan Stanley New York, NY5.31MShares$87 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$80 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $927M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...